SB 743921
Alternative Names: SB-743921; SB-921Latest Information Update: 02 Oct 2021
At a glance
- Originator Cytokinetics
- Class Antineoplastics; Benzopyrans; Small molecules
- Mechanism of Action KIF11 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Hodgkin's disease; Non-Hodgkin's lymphoma
Most Recent Events
- 06 Dec 2009 Interim adverse events & efficacy data from the phase I/II CY 2121 trial in Hodgkin's disease & Non-Hodgkin's lymphoma presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009) ,
- 02 Jun 2009 Interim efficacy & adverse events data from the phase I portion of a phase I/II trial in non-Hodgkin's lymphoma presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009)
- 24 Dec 2008 SB 743921 is no longer licensed to GlaxoSmithKline